Vam6 reduces iNKT cell function in tumor <i>via</i> modulating AMPK/mTOR pathways
Shiyu Bai,Qielan Wu,Shasha Zhu,Yuwei Zhang,Xuran Chen,Miya Su,Jun Pan,Shuhang Li,Ting Yue,Linfeng Xu,Di Xie,Chenxi Tian,Dan Zhao,Xiang Li,Junjie Hou,Lu Wang,Sicheng Fu,Yanhong Xue,Amin Jiang,Dong Li,Tao Xu,Zhigang Tian,Rongbin Zhou,Huimin Zhang,Li Bai
DOI: https://doi.org/10.3389/fimmu.2022.1051045
IF: 7.3
2023-01-01
Frontiers in Immunology
Abstract:Activation of mTORC1 is essential for anti-tumor function of iNKT cells. The mechanisms underlying impaired mTORC1 activation in intratumoral iNKT cells remain unclear. Via generating Vam6(+/-) mice and using flow cytometry, image approach, and RNA sequencing, we studied the role of Vam6 in controlling mTORC1 activation and intratumoral iNKT cell functions. Here, we find that increased Vam6 expression in intratumoral iNKT cells leads to impaired mTORC1 activation and IFN-gamma production. Mechanistically, Vam6 in iNKT cells is essential for Rab7a-Vam6-AMPK complex formation and thus for recruitment of AMPK to lysosome to activate AMPK, a negative regulator of mTORC1. Additionally, Vam6 relieves inhibitory effect of VDAC1 on Rab7a-Vam6-AMPK complex formation at mitochondria-lysosome contact site. Moreover, we report that lactic acid produced by tumor cells increases Vam6 expression in iNKT cells. Given the key roles of increased Vam6 in promoting AMPK activation in intratumoral iNKT cells, reducing Vam6 expression signifificantly enhances the mTORC1 activation in intratumoral iNKT cells as well as their anti-tumor effificacy. Together, we propose Vam6 as a target for iNKT cell-based immunotherapy.